Immucell (ICCC) Capital Expenditures (2010 - 2025)

Immucell (ICCC) has reported Capital Expenditures for 16 consecutive years, with $172306.0 the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Capital Expenditures fell 12.19% year-over-year to $172306.0; the trailing twelve-month figure through Dec 2025 stood at $1.3 million (up 168.49% YoY), and the FY2025 full-year result was $1.3 million, up 168.49% from the prior year.
• Capital Expenditures declined to $172306.0 in Q4 2025 per ICCC's latest filing, from $593924.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $1.5 million in Q4 2022 and bottomed at $70356.0 in Q1 2024.
• Historically, Capital Expenditures has averaged $509630.0 across 5 years, with a median of $507219.5 in 2023.
• The sharpest annual moves came in 2023 and 2025: Capital Expenditures slumped 94.54% in 2023, then soared 571.77% in 2025.
• Over 5 years, Capital Expenditures stood at $704594.0 in 2021, then soared by 111.49% to $1.5 million in 2022, then plunged by 94.54% to $81344.0 in 2023, then soared by 141.22% to $196216.0 in 2024, then fell by 12.19% to $172306.0 in 2025.
• According to Business Quant data, Capital Expenditures over the past three periods registered $172306.0, $593924.0, and $155159.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.